Ventria Biosciences (formerly known as Applied Phytologics Inc.)

Ventria Biosciences

Brief Description

Ventria Bioscience is a privately held biopharmaceutical company with a product pipeline enabled by ExpressTec. ExpressTec is a patented, plant-based recombinant protein manufacturing technology that delivers a ten-fold higher recombinant protein yield than other plant-based systems. Ventria Bioscience's platform technology delivers meaningful and sustainable economic advantages by enabling new product opportunities that were not previously available. It can be used to develop new biotherapeutics, novel vaccines, reagents for biomanufacturing, and industrial and biofuel enzymes.

Ventria Bioscience's internal Therapeutic Pipeline includes new human therapeutic products and vaccines for controlling zoonotic disease. Ventria Bioscience also provides access to its platform technology through contract manufacturing services. Ventria Bioscience has an extensive intellectual property portfolio of more than 100 issued patents, exclusive licenses to issued patents, and patents in prosecution. These patents provide long-term sustainable advantage to Ventria Bioscience's manufacturing technology and product portfolio.

As a startup, the fledgling Sacramento-based company signed an exclusive license for a technology for hypoallergenic wheat discovered by researchers in the UC Berkeley Plant and Microbial Biology Department. 

Formerly known as Applied Phytologics, Inc.


  • 1993. Company founded
  • 2002. Changed name to Ventria Biosciences
  • 2013. Company acquired by Synergenics, a consortium of commonly-owned but independent biotech companies
  • 2023. Ventria Bioscience sold its plant-made biomanufacturing technology to ExpressTec LLC


Bob Buchanan, Myeong-Je Cho, Peggy Lemaux